Webinar

Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and safety. In this webinar, we will explore WuXi XDC’s proprietary conjugation and payload-linker technology platform — a cutting-edge solution designed to overcome key challenges in ADC development. Discover how this platform enables the rational design of next-generation ADCs with enhanced therapeutic potential, offering greater precision, durability, and potential clinical benefits.
 
During the webinar, you’ll learn:

• Conjugation Technologies Landscape
  Gain a strategic overview of current conjugation technologies and learn how to select the optimal approach to advance your ADC program.
• Novel Conjugation Technology Platform: WuXiDARx™ & Beyond
  Explore WuXiDARx™, featuring clinically validated conjugation sites, improved homogeneity, flexible DARs, and simple CMC process, and other proprietary conjugation technologies.
• Next-Generation Payload-Linker Innovations
  Discover novel payload-linker technologies from WuXi XDC and partners, designed to improve efficacy and/or tolerability, as well as alternative payload release mechanism for next-gen ADCs.

Speaker:

Dr. Qirui Fan

Director of New Technology Development

WuXi XDC